Increased Plasma Chymase Concentration and Mast Cell Chymase Expression in Venous Neointimal Lesions of Patients with CKD and ESRD

Seminars in Dialysis

Volumn 24, Issue 6, 2011, Pages 688-693

  Wasse, Haimanot ^a   Rivera, Angel A ^a   Huang, Rong ^a   Martinson, Deborah E ^b   Long, Qi ^c   Mckinnon, William ^d   Naqvi, Nawazish ^b   Husain, Ahsan ^b  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c EMORY UNIVERSITY   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHYMASE;

ADULT; BIOSYNTHESIS; BLOOD; CHRONIC KIDNEY FAILURE; ENZYMOLOGY; FEMALE; HUMAN; MALE; MAST CELL; METABOLISM; MIDDLE AGED; NEOINTIMA; NOTE; VEIN;

ADULT; CHYMASES; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MAST CELLS; MIDDLE AGED; NEOINTIMA; VEINS; YOUNG ADULT;

EID: 83155175345     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2011.00921.x     Document Type: Note

References (43)

1. Roy-Chaudhury P, Arend L, Zhang J, Krishnamoorthy M, Wang Y, Banerjee R, Samaha A, Munda R: Neointimal hyperplasia in early arteriovenous fistula failure. Am J Kidney Dis 50:782-790, 2007
2. Roy-Chaudhury P, Kelly BS, Miller MA, Reaves A, Armstrong J, Nanayakkara N, Heffelfinger SC: Venous neointimal hyperplasia in polytetrafluoroethylene dialysis grafts. Kidney Int 59:2325-2334, 2001
3. Beaulieu MC, Gabana C, Rose C, MacDonald PS, Clement J, Kiaii M: Stenosis at the area of transposition-an under-recognized complication of transposed brachiobasilic fistulas. J Vasc Access 8:268-274, 2007
4. Quinn SF, Schuman ES, Hall L, Gross GF, Uchida BT, Standage BA, Rosch J, Ivancev K: Venous stenoses in patients who undergo hemodialysis: treatment with self-expandable endovascular stents. Radiology 183:499-504, 1992
5. Vorwerk D, Guenther RW, Mann H, Bohndorf K, Keulers P, Alzen G, Sohn M, Kistler D: Venous stenosis and occlusion in hemodialysis shunts: follow-up results of stent placement in 65 patients. Radiology 195:140-146, 1995
6. Gray RJ, Horton KM, Dolmatch BL, Rundback JH, Anaise D, Aquino AO, Currier CB, Light JA, Sasaki TM: Use of Wallstents for hemodialysis access-related venous stenoses and occlusions untreatable with balloon angioplasty. Radiology 195:479-484, 1995
7. Stone GW, Rizvi A, Newman W, Mastali K, Wang JC, Caputo R, Doostzadeh J, Cao S, Simonton CA, Sudhir K, Lansky AJ, Cutlip DE, Kereiakes DJ: Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med 362:1663-1674, 2010
8. Kedhi E, Joesoef KS, McFadden E, Wassing J, van Mieghem C, Goedhart D, Smits PC: Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet 75:201-209, 2010
9. Goldman S, Zadina K, Moritz T, Ovitt T, Sethi G, Copeland JG, Thottapurathu L, Krasnicka B, Ellis N, Anderson RJ, Henderson W: Long-term patency of saphenous vein and left internal mammary artery grafts after coronary artery bypass surgery: results from a Department of Veterans Affairs Cooperative Study. J Am Coll Cardiol 44:2149-2156, 2004
10. Garg S, Serruys PW: Coronary stents: current status. J Am Coll Cardiol 56(10 Suppl.):S1-S42, 2010
11. Brilakis ES, Saeed B, Banerjee S: Drug-eluting stents in saphenous vein graft interventions: a systematic review. EuroIntervention 5:722-730, 2010
12. Schwab SJ, Harrington JT, Singh A, Roher R, Shohaib SA, Perrone RD, Meyer K, Beasley D: Vascular access for hemodialysis. Kidney Int 55:2078-2090, 1999
13. Daemen MJ, Lombardi DM, Bosman FT, Schwartz SM: Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res 68:450-456, 1991
14. Griffin SA, Brown WC, MacPherson F, McGrath JC, Wilson VG, Korsgaard N, Mulvany MJ, Lever AF: Angiotensin II causes vascular hypertrophy in part by a non-pressor mechanism. Hypertension 17:626-635, 1991
15. Su EJ, Lombardi DM, Siegal J, Schwartz SM: Angiotensin II induces vascular smooth muscle cell replication independent of blood pressure. Hypertension 31:1331-1337, 1998
16. Hermans WR, Rensing BJ, Foley DP, Deckers JW, Rutsch W, Emanuelsson H, Danchin N, Wijns W, Chappuis F, Serruys PW: Therapeutic dissection after successful coronary balloon angioplasty: no influence on restenosis or on clinical outcome in 693 patients. The MERCATOR Study Group (Multicenter European Research Trial with Cilazapril after Angioplasty to prevent Transluminal Coronary Obstruction and Restenosis). J Am Coll Cardiol 20:767-780, 1992
17. Faxon DP: Effect of high dose angiotensin-converting enzyme inhibition on restenosis: final results of the MARCATOR Study, a multicenter, double-blind, placebo-controlled trial of cilazapril. The Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR) Study Group. J Am Coll Cardiol 25:362-369, 1995
18. Peters S, Gotting B, Trummel M, Rust H, Brattstrom A: Valsartan for prevention of restenosis after stenting of type B2/C lesions: the VAL-PREST trial. J Invasive Cardiol 13:93-97, 2001
19. Peters S, Trummel M, Meyners W, Koehler B, Westermann K: Valsartan versus ACE inhibition after bare metal stent implantation-results of the VALVACE trial. Int J Cardiol 98:331-335, 2005
20. Chung IM, Gold HK, Schwartz SM, Ikari Y, Reidy MA, Wight TN: Enhanced extracellular matrix accumulation in restenosis of coronary arteries after stent deployment. J Am Coll Cardiol 40:2072-2081, 2002
21. Nabel EG, Shum L, Pompili VJ, Yang ZY, San H, Shu HB, Liptay S, Gold L, Gordon D, Derynck R: Direct transfer of transforming growth factor beta 1 gene into arteries stimulates fibrocellular hyperplasia. Proc Natl Acad Sci U S A 90:10759-10763, 1993
22. Schulick AH, Taylor AJ, Zuo W, Qiu CB, Dong G, Woodward RN, Agah R, Roberts AB, Virmani R, Dichek DA: Overexpression of transforming growth factor beta1 in arterial endothelium causes hyperplasia, apoptosis, and cartilaginous metaplasia. Proc Natl Acad Sci U S A 95:6983-6988, 1998
23. Gibbons GH, Pratt RE, Dzau VJ: Vascular smooth muscle cell hypertrophy vs. hyperplasia. Autocrine transforming growth factor-beta 1 expression determines growth response to angiotensin II. J Clin Invest 90:456-461, 1992
24. Tchougounova E, Lundequist A, Fajardo I, Winberg JO, Abrink M, Pejler G: A key role for mast cell chymase in the activation of pro-matrix metalloprotease-9 and pro-matrix metalloprotease-2. J Biol Chem 280:9291-9296, 2005
25. Lindstedt KA, Wang Y, Shiota N, Saarinen J, Hyytiainen M, Kokkonen JO, Keski-Oja J, Kovanen PT: Activation of paracrine TGF-beta1 signaling upon stimulation and degranulation of rat serosal mast cells: a novel function for chymase. FASEB J 15:1377-1388, 2001
26. Zhao XY, Zhao LY, Zheng QS, Su JL, Guan H, Shang FJ, Niu XL, He YP, Lu XL: Chymase induces profibrotic response via transforming growth factor-beta 1/Smad activation in rat cardiac fibroblasts. Mol Cell Biochem 310:159-166, 2008
27. Takai S, Sakonjo H, Fukuda K, Jin D, Sakaguchi M, Kamoshita K, Ishida K, Sukenaga Y, Miyazaki M: A novel chymase inhibitor, 2-(5-formylamino-6-oxo-2-phenyl-1, 6-dihydropyrimidine-1-yl)-N-[[, 4-dioxo-1-phenyl-7-(2-pyridyloxy)]2-heptyl]acetamide (NK3201), suppressed intimal hyperplasia after balloon injury. J Pharmacol Exp Ther 304:841-844, 2003
28. Nishimoto M, Takai S, Kim S, Jin D, Yuda A, Sakaguchi M, Yamada M, Sawada Y, Kondo K, Asada K, Iwao H, Sasaki S, Miyazaki M: Significance of chymase-dependent angiotensin II-forming pathway in the development of vascular proliferation. Circulation 104:1274-1279, 2001
29. Jin D, Ueda H, Takai S, Muramatsu M, Furubayashi K, Ibaraki T, Kishi K, Katsuoka Y, Miyazaki M: Roles of chymase in stenosis occurring after polytetrafluoroethylene graft implantations. Life Sci 81:1291-1300, 2007
30. Jin D, Ueda H, Takai S, Okamoto Y, Muramatsu M, Sakaguchi M, Shibahara N, Katsuoka Y, Miyazaki M: Effect of chymase inhibition on the arteriovenous fistula stenosis in dogs. J Am Soc Nephrol 16:1024-1034, 2005
31. Tsai S, Hollenbeck ST, Ryer EJ, Edlin R, Yamanouchi D, Kundi R, Wang C, Liu B, Kent KC: TGF-beta through Smad3 signaling stimulates vascular smooth muscle cell proliferation and neointimal formation. Am J Physiol Heart Circ Physiol 297:H540-H549, 2009
32. Heine GH, Ulrich C, Sester U, Sester M, Kohler H, Girndt M: Transforming growth factor beta1 genotype polymorphisms determine AV fistula patency in hemodialysis patients. Kidney Int 64:1101-1107, 2003
33. Marrone D, Pertosa G, Simone S, Loverre A, Capobianco C, Cifarelli M, Memoli B, Schena FP, Grandaliano G: Local activation of interleukin 6 signaling is associated with arteriovenous fistula stenosis in hemodialysis patients. Am J Kidney Dis 49:664-673, 2007
34. De Marchi S, Falleti E, Giacomello R, Stel G, Cecchin E, Sepiacci G, Bortolotti N, Zanello F, Gonano F, Bartoli E: Risk factors for vascular disease and arteriovenous fistula dysfunction in hemodialysis patients. J Am Soc Nephrol 7:1169-1177, 1996
35. Raymond WW, Su S, Makarova A, Wilson TM, Carter MC, Metcalfe DD, Caughey GH: Alpha 2-macroglobulin capture allows detection of mast cell chymase in serum and creates a reservoir of angiotensin II-generating activity. J Immunol 182:5770-5777, 2009
36. Laine P, Kaartinen M, Penttila A, Panula P, Paavonen T, Kovanen PT: Association between myocardial infarction and the mast cells in the adventitia of the infarct-related coronary artery. Circulation 99:361-369, 1999
37. Richard V, Hurel-Merle S, Scalbert E, Ferry G, Lallemand F, Bessou JP, Thuillez C: Functional evidence for a role of vascular chymase in the production of angiotensin II in isolated human arteries. Circulation 104:750-752, 2001
38. Verrecchia F, Mauviel A: Transforming growth factor-beta signaling through the Smad pathway: role in extracellular matrix gene expression and regulation. J Invest Dermatol 118:211-215, 2002
39. Wolf YG, Rasmussen LM, Ruoslahti E: Antibodies against transforming growth factor-beta 1 suppress intimal hyperplasia in a rat model. J Clin Invest 93:1172-1178, 1994
40. Koibuchi Y, Lee WS, Gibbons GH, Pratt RE: Role of transforming growth factor-beta 1 in the cellular growth response to angiotensin II. Hypertension 21(6 Pt 2):1046-1050, 1993
41. Taipale J, Lohi J, Saarinen J, Kovanen PT, Keski-Oja J: Human mast cell chymase and leukocyte elastase release latent transforming growth factor-beta 1 from the extracellular matrix of cultured human epithelial and endothelial cells. J Biol Chem 270:4689-4696, 1995
42. Hugle T, Hogan V, White K, van Laar JM: Mast cells are a source of transforming growth factor (TGF) beta in systemic sclerosis. Arthritis Rheum 63(3):795-799, 2011
43. Sun J, Zhang J, Lindholt JS, Sukhova GK, Liu J, He A, Abrink M, Pejler G, Stevens RL, Thompson RW, Ennis TL, Gurish MF, Libby P, Shi GP: Critical role of mast cell chymase in mouse abdominal aortic aneurysm formation. Circulation 120:973-982, 2009